Edition:
United Kingdom

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

7.24USD
6:37pm BST
Change (% chg)

$-0.07 (-0.96%)
Prev Close
$7.31
Open
$7.28
Day's High
$7.55
Day's Low
$7.19
Volume
184,131
Avg. Vol
210,667
52-wk High
$8.13
52-wk Low
$4.12

Chart for

About

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry... (more)

Overall

Beta: 3.23
Market Cap(Mil.): $420.84
Shares Outstanding(Mil.): 80.47
Dividend: --
Yield (%): --

Financials

  BCRX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.62 -- --
ROI: -116.97 1.78 14.61
ROE: -251.64 3.27 16.33

BRIEF-Biocryst Pharmaceuticals Q1 Loss Per Share $0.26

* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S

08 May 2018

BRIEF-BioCryst Receives European Medicines Agency Approval For Alpivab For Treatment Of Influenza

* BIOCRYST RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL FOR ALPIVAB™ FOR TREATMENT OF INFLUENZA Source text for Eikon: Further company coverage:

01 May 2018

BRIEF-Biocryst Pharmaceuticals And Idera Pharmaceuticals Reschedule Meetings To Vote On Proposed Merger

April 10 Idera Pharmaceuticals Inc - New Clinical Data On Idera's Imo :

10 Apr 2018

BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst

* IDERA PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH BIOCRYST PHARMACEUTICALS

02 Apr 2018

BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals

* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS

02 Apr 2018

BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals

* BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS

02 Apr 2018

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥4,830 +140.00
Eisai Co., Ltd (4523.T) ¥10,270 -330.00
Roche Holding Ltd. (ROG.S) CHF235.15 +0.10
Roche Holding Ltd. (RO.S) CHF235.40 -1.20
GlaxoSmithKline plc (GSK.L) 1,531.40 +45.60
Shire PLC (SHP.L) 4,569.00 +60.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates